Core Viewpoint - The recent surge in Guangkang Biochemical's stock price has prompted major shareholders to initiate significant share reduction plans, potentially leading to substantial cashing out opportunities for them [1][2]. Group 1: Shareholder Actions - Guangkang Biochemical announced two share reduction plans from shareholders holding over 5% of the company's shares, with a total potential reduction of up to 6% of the company's total shares [1]. - The shareholders involved plan to reduce their holdings by a maximum of 222,000 shares each, which represents 3% of the total share capital [1]. - If the maximum reduction occurs at the closing price of 44.68 yuan per share on June 3, the total cashing out could reach approximately 198 million yuan [1]. Group 2: Stock Price Movement - From May 27 to June 3, Guangkang Biochemical's stock price increased from 26.53 yuan to 44.68 yuan, marking a significant rise of 68% over just five trading days [2]. - The stock price decline of over 13% on June 4 was likely influenced by the announcement of the major share reduction plans [3]. Group 3: Company Performance - Guangkang Biochemical's revenue and net profit have shown a notable decline in 2023, with revenues of 495 million yuan and a net profit of 30.07 million yuan, representing decreases of 24.99% and 68.73% year-on-year, respectively [3]. - The company's profitability has been declining, with a continuous drop in gross margin from 33.44% in Q1 2022 to 30.15% in Q1 2023 [4].
广康生化股价5天涨68%股东拟减持6% 首季净利再下滑毛利率三连降